Compare Novartis AG (NVS) vs Union Pacific Corporation (UNP) Price & Performance

Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.

The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.

Union Pacific (UNP) trades at $293.85, up 0.55% with neutral technical signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating estimates at $3.41 versus $3.26 expected, marking the second consecutive quarterly beat. Revenue growth of 12% year-over-year and improved operating efficiency support management's raised full-year EPS guidance. The stock maintains robust profitability metrics including 28.85% net margin and 39.7% ROE, though valuation multiples remain elevated with P/E at 23.71.

Outlook remains positive with analyst consensus price target of $334.33 representing 14% upside potential. Key catalysts include service-led growth driving margin expansion and the pending Norfolk Southern merger offering strategic benefits. Risks include high fuel costs, regulatory scrutiny of the merger, and macroeconomic pressures on freight volumes. Institutional ownership trends show continued accumulation by major funds.